Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Sees Large Decline in Short Interest

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 10,400 shares, a decline of 46.1% from the January 31st total of 19,300 shares. Based on an average daily trading volume, of 2,030,000 shares, the short-interest ratio is currently 0.0 days. Currently, 0.7% of the company’s stock are short sold.

Salarius Pharmaceuticals Price Performance

Shares of SLRX traded down $0.15 during mid-day trading on Friday, reaching $1.08. The company’s stock had a trading volume of 257,839 shares, compared to its average volume of 3,351,676. Salarius Pharmaceuticals has a 12-month low of $0.91 and a 12-month high of $7.20. The stock has a market cap of $1.71 million, a PE ratio of -0.13 and a beta of 0.84. The company’s 50 day moving average is $1.93 and its 200 day moving average is $1.69.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.